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Since December 2016, excess all-cause mortality was 
observed in many European countries, especially 
among people aged ≥ 65 years. We estimated all-cause 
and influenza-attributable mortality in 19 European 
countries/regions. Excess mortality was primarily 
explained by circulation of influenza virus A(H3N2). 
Cold weather snaps contributed in some countries. The 
pattern was similar to the last major influenza A(H3N2) 
season in 2014/15 in Europe, although starting earlier 
in line with the early influenza season start.
During winter seasons in Europe, an increase in all-
cause mortality is often observed. This excess mor-
tality may vary considerably between countries, by 
age group and from one season to another [1-5]. 
Circulation of influenza virus, in particular with the 
subtype A(H3N2), has been shown to be the main sea-
sonal driver of excess mortality, particularly among 
the elderly (≥ 65 years of age), but other factors such 
as other respiratory agents and extreme cold weather 
may contribute as well [6-10]. In the current 2016/17 
winter season, from the end of 2016 and until calen-
dar week 8/2017, marked excess all-cause mortality 
was observed in many countries participating in the 
network for European monitoring of excess mortality 
for public health action (EuroMOMO), particularly in 
people 65 years and older, but also among those aged 
15–64 years. Here we describe the excess all-cause 
mortality and estimate the influenza-attributable mor-
tality for the current winter season until calendar week 
8/2017 in Europe.
European monitoring of excess mortality 
for public health action
Since 2009, the EuroMOMO network (www.euromomo.
eu) has monitored weekly all-cause age group-spe-
cific excess mortality in several European countries. 
EuroMOMO uses a statistical algorithm, which allows 
for comparison and pooling of national and regional 
mortality data [4]. More recently, influenza activity (IA) 
data, based on reported national rates of influenza-
like illness (ILI) or acute respiratory infection (ARI), or, 
if not available, based on reported intensity of IA (cat-
egorised as low, medium, high, very high), is used to 
estimate the burden of influenza-attributable mortal-
ity, applying a statistical algorithm known as FluMOMO 
[11].
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Figure 1
Number of all-cause deaths by week and modelled baseline from pooled analysis of data, participating EuroMOMO 
countries/regions, calendar week 25/2013 until week 8/2017
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EuroMOMO: European monitoring of excess mortality for public health action; UK: United Kingdom.
Participating countries: Belgium, Denmark, England (UK), Estonia, Finland, France, Greece, Hungary, Ireland, Italy, Malta, the Netherlands, 
Norway, Portugal, Scotland (UK), Spain, Sweden, Switzerland and Wales (UK).
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Estimation of all-cause mortality
Countries in the EuroMOMO network collected weekly 
data on the number of deaths from all causes, and 
excess (deviation from baseline) all-cause num-
ber of deaths was estimated using the EuroMOMO 
statistical algorithm described previously [4]. Staff 
at the EuroMOMO hub at Statens Serum Institut in 
Copenhagen, Denmark, compiled weekly data from 
individual countries and conducted a pooled analy-
sis using an age-stratified method [7], which included 
data from 19 European countries or regions (Belgium, 
Denmark, England (United Kingdom (UK)), Estonia, 
Finland, France, Greece, Hungary, Ireland, Italy, Malta, 
the Netherlands, Norway, Portugal, Scotland (UK), 
Spain, Sweden, Switzerland and Wales (UK)). We used 
z-scores to standardise outputs enabling comparisons 
of mortality patterns between different countries and 
between different time-periods. Estimates are shown 
as totals (all age groups) and stratified by age groups 
(< 5, 5–14, 15–64 and ≥ 65 years). The pooled analysis 
covers all-cause mortality up to and including calendar 
week 8/2017, based on data received by week 9/2017.
We also calculated the cumulative excess all-cause 
mortality for the current winter season and compared 
it with the previous winter seasons of 2013/14, 2014/15 
and 2015/16. Winter seasons are defined as the period 
between calendar week 40 in a given year and week 20 
in the following year.
Estimation of influenza-attributable mortality
The number of influenza-attributable deaths in the 
EuroMOMO network countries was estimated using 
the FluMOMO algorithm, based on weekly IA data 
(ILI, ARI or intensity data, as available) from the par-
ticipating 19 EuroMOMO countries, retrieved from the 
TESSy database at the European Centre for Disease 
Prevention and Control (ECDC) [12]. The model is a 
multiplicative Poisson regression time-series model 
with over-dispersion and International Organization 
for Standardization (ISO)-week as time unit. As in the 
EuroMOMO model, the multiplicative residual variance 
is post-regression corrected for skewness by applying 
a 2/3-power correction [13]. As the dominant type/sub-
type of influenza viruses circulating varies from season 
to season, a separate effect of IA for each season is 
used. To adjust for a possible confounding effect of 
temperature, an explanatory variable reflecting ambi-
ent temperature deviation from expected normal tem-
perature is included in the model, obtained for each 
of the countries from the respective National Oceanic 
and Atmospheric Administration (NOAA). Further, two 
weeks delayed effects of the explanatory variables 
are also included in the model. The model estimates 
both a baseline and the effect of IA and temperature 
simultaneously, i.e. controlled for one another. IA data 
from the same countries and for the same time period 
as used to calculate the all-cause mortality, mentioned 
above, was used.
Based on the estimated number of deaths, mortality 
rates were calculated using national population data 
downloaded from EuroStat, as at 1 January 2017, and 
linearly interpolated.
Influenza sentinel surveillance data
Weekly proportions of primary care sentinel speci-
mens testing positive for influenza in the participating 
EuroMOMO network countries that had experienced 
excess mortality in the 2016/17 winter season were 
analysed and compared with previous seasons since 
2011/12 [14].
Figure 2
Cumulated pooled excess all-cause mortality, participating 
EuroMOMO countries/regions, winter seasons 2013/14, 
2014/15, 2015/16 and 2016/17 (until week 8/2017)
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EuroMOMO: European monitoring of excess mortality for public 
health action; UK: United Kingdom.
Participating countries: Belgium, Denmark, England (UK), Estonia, 
Finland, France, Greece, Hungary, Ireland, Italy, Malta, the 
Netherlands, Norway, Portugal, Scotland (UK), Spain, Sweden, 
Switzerland and Wales (UK).
Winter seasons: period between calendar week 40 in a given year 
and week 20 in the following year.
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Results
All-cause mortality started to exceed normal lev-
els in Portugal around calendar week 50/2016. Soon 
after, excess mortality was also detected in many 
other EuroMOMO network countries, including the 
following (mentioned in alphabetic order): Belgium, 
England (UK), Finland, France, Greece, Ireland, Italy, 
Malta, the Netherlands, Norway, Scotland (UK), Spain, 
Switzerland and Wales (UK). Countries in southern 
Europe experienced particularly high excess mortal-
ity levels. The observed excess all-cause mortality 
was most prominent in individuals aged 65 years and 
older, but some countries also observed excess deaths 
among those aged 15–64 years. At week 8/2017 mortal-
ity levels were still elevated in most of the reporting 
countries and only three countries, Denmark, Estonia 
and Hungary had not observed any significant excess 
mortality in 2016/17.
Evaluation of the pooled excess all-cause mortality 
of the 19 participating European countries/regions 
revealed a sharp rise in mortality among individuals 
aged 65 years and older, starting around the turn of the 
year and exceeding 4 z-scores above baseline in calen-
dar week 2/2017 (Figure 1).
The cumulated pooled excess (deviation from baseline) 
all-cause mortality observed in the 2016/17 winter sea-
son compared with the previous three winter seasons 
(Figure 2) showed that excess mortality in those aged 
65 years and older reached considerable excess lev-
els. The pattern resembled that of the severe 2014/15 
season albeit with a few weeks´ earlier onset of the 
increase, in line with an earlier onset of influenza virus 
circulation in 2016/17 (Figure 3).
Seasonal variation in excess mortality estimates for 
the 19 participating countries/regions, derived from 
the FluMOMO model output, could primarily be attrib-
uted to seasonal variation in influenza activity (Figure 
4).
In this model, IA seemed to be an important driver of 
the observed overall excess winter mortality (Table). 
The estimated pooled excess all-cause winter mortal-
ity among people aged 65 years and older according 
to the EuroMOMO model reached 158 (95% confidence 
interval (CI): 153–162) deaths per 100,000 population 
for the 2016/17 season (until week 8/2017), compared 
with 208 (95% CI: 202–214) for the whole season of 
2014/15, and they were well above the 2013/14 and 
2015/16 seasons estimates (Table). The same pattern 
was observed for the estimated cumulated influenza-
attributable mortality using FluMOMO, with 137 (range: 
76–302) deaths per 100,000 population in the 2016/17 
winter season (until week 8/2017), compared with 185 
(range: 82–311) in the winter season of 2014/15 (Table).
Figure 3
Weekly proportions of influenza-positive primary care sentinel specimens and threshold of 10% positivity, participating 
EuroMOMO countries/regionsa, winter seasons 2013/14 to 2016/17 (until week 8/2017)
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EuroMOMO: European monitoring of excess mortality for public health action.
a Countries included in the graph, that experienced excess mortality in the 2016/2017 season, are: Belgium, Finland, France, Ireland, Italy, 
Malta, The Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and United Kingdom.
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Discussion
As at week 8/2017 of the 2016/17 winter season in 
Europe, influenza virus A(H3N2) predominated and 
circulated widely, and a large number of European 
countries experienced markedly increased mortal-
ity levels, particularly in their elderly populations. 
The EuroMOMO pooled analysis showed that this 
years’ excess mortality started earlier than what was 
observed across Europe during the previous influenza 
A(H3N2) predominant season in 2014/15. The esti-
mates of mortality attributable to IA, from FluMOMO, 
showed a similar pattern. The pooled estimates of all-
cause and influenza-attributable mortality in 2016/17 
at week 8/2017 were slightly lower than the estimates 
from the 2014/15 season, but this may change as the 
season progresses.
Pooled estimates may mask important local differ-
ences in influenza-attributable mortality, including 
effects of extreme temperatures in some countries. 
Indeed, many parts of Europe were affected by very 
cold weather in January 2017 which may have had an 
impact on the all-cause excess mortality. Therefore, 
we estimated the influenza-attributable deaths among 
older adults adjusting for extreme temperatures. We 
found that throughout Europe the excess mortality was 
mainly explained by the early peak and widespread cir-
culation of influenza A(H3N2), the influenza virus most 
frequently associated with fatal influenza in the elderly 
[14,15]. Indeed, influenza morbidity and mortality put 
a significant strain on health facilities and hospitals 
in many countries across Europe in the first weeks of 
2017 [14].
The scenario during this influenza season in Europe 
seemed remarkably similar to the season in 2014/15. 
That season was also characterised by a sharp rise in 
mortality in the elderly coinciding with widespread cir-
culation of influenza A(H3N2) virus in many countries, 
as also detected and reported through the EuroMOMO 
mortality monitoring system [5]. The A(H3N2) virus 
strain that circulated in 2014/15 had drifted consider-
ably from the strain chosen as the A(H3N2) component 
in the seasonal vaccine, possibly also contributing to 
the excess mortality among the elderly, the key target 
group for vaccinations in Europe. Interim estimates of 
the 2016/17 vaccine effectiveness have shown only 
a moderate effectiveness against influenza A(H3N2) 
both in Europe [16,17] and in North America [18,19]. 
Therefore, rapid use of neuraminidase inhibitors and 
supportive care for any confirmed or probable case 
of influenza infection should be considered for the 
management of vaccinated as well as non-vaccinated 
patients at risk of developing severe illness and 
complications.
EuroMOMO has proven a valuable network for timely 
detection and reporting of excess all-cause mortality 
across many parts of Europe in a coordinated man-
ner. In this report we also provide for the first time 
results from the FluMOMO statistical model pilot, 
which enables us to demonstrate how IA affects mor-
tality, adjusted for the confounding effect of deviations 
from expected ambient temperatures, like extreme 
cold temperatures. This is an important advance in 
the rapid risk assessment of seasonal influenza. Our 
approach and experiences in ‘real-time’ monitoring of 
excess mortality may contribute to improving regional 
and global estimation of the severity of ongoing influ-
enza seasons, or a developing influenza pandemic, in 
Figure 4
Weekly all-cause and influenza-attributable mortality 
rates (deaths per 100,000 people per week), participating 
EuroMOMO countries, winter seasons 2013/14 to 2016/17 
(until week 8/2017)
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health action; UK United Kingdom.
Estimates are calculated with the FluMOMO model (see main text 
for details).
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cause deaths from the estimated baseline. The red curves signify 
mortality attributable to influenza activity.
Participating countries: Belgium, Denmark, England (UK), Estonia, 
Finland, France, Greece, Hungary, Ireland, Italy, Malta, the 
Netherlands, Norway, Portugal, Scotland (UK), Spain, Sweden, 
Switzerland and Wales (UK).
Winter seasons: period between calendar week 40 in a given year 
and week 20 in the following year.
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a timely manner. Based on its relatively simple techni-
cal and operational features, the use of the FluMOMO 
model may provide a user-friendly, yet powerful, tool 
for rapid public health action.
Despite the results presented here, further validation of 
the described approach is warranted. For instance, we 
need to explore the use of different influenza param-
eters, as clinical indicators of respiratory disease such 
as ILI and ARI on their own may not be the best indica-
tors of influenza-attributable mortality and influenza 
virus circulation. Nonetheless, the use of such routine 
influenza surveillance data has proven valuable for the 
monitoring of the community impact of influenza at 
the European level [20]. The practicalities of retrieving 
national IA data directly from TESSy at ECDC [12] need 
further evaluation and optimisation before the proce-
dure can be set up and operated on a routine basis. We 
will continue to conduct further in-depth analysis and 
validations of the FluMOMO model, aiming to develop 
an even more reliable and time-effective tool to moni-
tor the severity of seasonal influenza in Europe and 
beyond.
The winter season has not ended yet and additional 
excess mortality may still emerge. We have noted some 
heterogeneity in mortality patterns across participat-
ing countries, which may reflect some real differences 
between countries, possibly related to varying levels 
of influenza virus circulation, due to country-specific 
population susceptibility or other contributing factors, 
such as differences in influenza vaccine policy and 
uptake. We will, therefore, continue to monitor the situ-
ation closely in the coming weeks and months.
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